WO2019150173A1 - Tibo (topical innovative burn ointment) - Google Patents
Tibo (topical innovative burn ointment) Download PDFInfo
- Publication number
- WO2019150173A1 WO2019150173A1 PCT/IB2018/050695 IB2018050695W WO2019150173A1 WO 2019150173 A1 WO2019150173 A1 WO 2019150173A1 IB 2018050695 W IB2018050695 W IB 2018050695W WO 2019150173 A1 WO2019150173 A1 WO 2019150173A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- verapamil
- topical
- healing
- inflammation
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 7
- 230000000699 topical effect Effects 0.000 title description 6
- 229960001722 verapamil Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 3
- 231100000241 scar Toxicity 0.000 claims abstract description 3
- 108010053950 Teicoplanin Proteins 0.000 claims abstract 3
- 208000032544 Cicatrix Diseases 0.000 claims abstract 2
- 230000000845 anti-microbial effect Effects 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 229960004194 lidocaine Drugs 0.000 claims abstract 2
- 230000037387 scars Effects 0.000 claims abstract 2
- 229960001608 teicoplanin Drugs 0.000 claims abstract 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 9
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000036573 scar formation Effects 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 150000001622 bismuth compounds Chemical class 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000006208 topical dosage form Substances 0.000 claims 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- -1 amalodipine Chemical compound 0.000 claims 1
- 229960003665 bepridil Drugs 0.000 claims 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 229960003580 felodipine Drugs 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229960004427 isradipine Drugs 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 229960001783 nicardipine Drugs 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960000715 nimodipine Drugs 0.000 claims 1
- 229960000227 nisoldipine Drugs 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000035876 healing Effects 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- BJNLLBUOHPVGFT-CAYRISATSA-N (1S,2R,19R,22R,34S,37R,40R,52S)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-22-amino-5,15-dichloro-64-[(2S,3R,4R,5S,6R)-3-(decanoylamino)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-26,31,44,49-tetrahydroxy-21,35,38,54,56,59-hexaoxo-47-[(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic acid Chemical compound CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(OC4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl BJNLLBUOHPVGFT-CAYRISATSA-N 0.000 abstract 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229920000153 Povidone-iodine Polymers 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000002262 irrigation Effects 0.000 abstract 1
- 238000003973 irrigation Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 229960001621 povidone-iodine Drugs 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract 1
- 229940049565 targocid Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 5
- 239000003883 ointment base Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
Definitions
- the present invention relates to the treatment of burns including ointments and other topical preparations and formulations useful for the delivery of medicaments.
- ointment base that can be used as a vehicle for a wide variety of medicaments and with a broad range of medicament volumes and concentrations.
- the ointment base of the present invention is prepared using a combination of commonly available ingredients identified as “generally recognized as safe” (“GRAS").
- GRAS generally recognized as safe
- the term “ointment base” refers to a mixture of ingredients of the final formulation other than the medicament solution which will allow the topically applicable formulations to be efficacious and have a proper time-release manner.
- medicament solution it refers to the active agent or any other agent to be delivered dermatologically, in whatever vehicle or form used to combine it with the ointment base.
- formulation refers to the combination of the ointment base and one or more medicament solutions to create the desired topical treatment.
- the degree of thermal damage is characterized by the zones of coagulation, stasis and hyperaemia.
- the zone of coagulation is where all the tissue is damaged but the pathophysiological changes in the zone of hyperaemia are spontaneously reversible.
- the zone of stasis although not immediately destroyed, converts to necrosis during the first week after injury owing to a fatal combination of several factors.
- the healing of a burn wound proceeds from the zone of hyperaemia and follows the same course as in a surgical wound. Modifications of the healing process are produced by the graded nature of the thermal injury and by the presence of coagulated tissue acting as a foreign body.
- Burn wound depth is an important determinant of patient morbidity and mortality. Therefore, reduction or even the prevention of secondary burn wound progression is one goal of the acute care of burned patients.
- Second Degree Burns They are also called superficial burns; they cause minimal skin damage. Signs and symptoms include:
- Second Degree Burns They are also called partial thickness burns; these affect the epidermis and dermis. Signs and symptoms include:
- Verapamil a Calcium-Channel Blocker, Improves the Wound Healing Process in Rats with Excisional Full-Thickness Skin Wounds Based on Stereological Parameters. https://www.ncbi.nlm.nih.gov/pubmed/27429235
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The treatment proposed by this invention is focusing on: - Reducing: pain, inflammation, and infection - Promoting healing process It Consists of: - Isopropyl Myristate, NF (Cosmetic Grade) 532 mL - Lidocaine 2% - Bismuth Salicylates 50 mg - Teicoplanin (Targocid) 400 mg - Verapamil HCl 4.8g Method: After irrigation of the burned area with normal saline and sterilization with povidone iodine solution, the ointment is put on a sterilized gauze and used to cover the burned area, then a dressing is made Q.O.D. (every other day). Results should begin to appear starting from one week after the initiation of the treatment, showing the following: - Safety, efficacy, and gentleness - Enhancement of tissue healing - Antimicrobial Effectiveness - Efficacy for burn related pain - Healing of inflammation - Prevention and treatment of Scars formation.
Description
TOPICAL INNOVATIVE BURN OINTMENT
Ointment for Burns (first and second degrees burns)
The present invention relates to the treatment of burns including ointments and other topical preparations and formulations useful for the delivery of medicaments.
This provides an ointment base that can be used as a vehicle for a wide variety of medicaments and with a broad range of medicament volumes and concentrations. The ointment base of the present invention is prepared using a combination of commonly available ingredients identified as "generally recognized as safe" ("GRAS"). The term “ointment base” refers to a mixture of ingredients of the final formulation other than the medicament solution which will allow the topically applicable formulations to be efficacious and have a proper time-release manner. As for the term "medicament solution", it refers to the active agent or any other agent to be delivered dermatologically, in whatever vehicle or form used to combine it with the ointment base. Lastly, the word "formulation” refers to the combination of the ointment base and one or more medicament solutions to create the desired topical treatment.
Innovative treatment for first and second degrees burns
To give an effective management for burns, the pathophysiology of the injury must be well understood.
The degree of thermal damage is characterized by the zones of coagulation, stasis and hyperaemia.
The zone of coagulation is where all the tissue is damaged but the pathophysiological changes in the zone of hyperaemia are spontaneously reversible. The zone of stasis, although not immediately destroyed, converts to necrosis during the first week after injury owing to a fatal combination of several factors. The healing of a burn wound proceeds from the zone of hyperaemia and follows the same course as in a surgical wound. Modifications of the healing process are produced by the graded nature of the thermal injury and by the presence of coagulated tissue acting as a foreign body.
Attempts to reduce the secondary tissue loss concentrate on the zone of stasis to which the damage is considered potentially reversible. Therapeutic measures positively influencing the pathophysiological processes in a burn wound are discussed.
After a burn injury, superficial partial-thickness burn wounds may progress to deep partial-thickness or full-thickness burn wounds, if kept untreated. This phenomenon is called secondary burn wound progression or conversion. Burn wound depth is an important determinant of patient morbidity and mortality. Therefore, reduction or even the prevention of secondary burn wound progression is one goal of the acute care of burned patients.
First Degree Burns: They are also called superficial burns; they cause minimal skin damage. Signs and symptoms include:
Redness
Signs of inflammation and swelling
Pain and tenderness
Second Degree Burns: They are also called partial thickness burns; these affect the epidermis and dermis. Signs and symptoms include:
Blisters
Redness
Inflammation and swelling
Pain
Peeling skin
Treatment of burns with good healing
Prevention of any infectious complication, reduction in pain and in scar formation
Medical
Verapamil, a Calcium-Channel Blocker, Improves the Wound Healing Process in Rats with Excisional Full-Thickness Skin Wounds Based on Stereological Parameters. https://www.ncbi.nlm.nih.gov/pubmed/27429235
Gel ointment of verapamil for percutaneous absorption. https://www.ncbi.nlm.nih.gov/pubmed/3509338
Topical Application of a Silicone Gel Sheet with Verapamil Microparticles in a Rabbit Model of Hypertrophic Scar. https://www.ncbi.nlm.nih.gov/pubmed/26710018
Increased calcium levels alter cellular and molecular events in wound healing. https://www.ncbi.nlm.nih.gov/pubmed/2555928
[Pathophysiology of the burn wound]. https://www.ncbi.nlm.nih.gov/pubmed/4076854
Topical Antimicrobials for Burn Wound Infections https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935806/
"Corygest" Unlisted Drugs (Mar. 1982) vol. 34, No. 3, pp. 38.
Claims (6)
- What is claimed is the following:
- A method of stimulating cellular production or release of growth factors, comprising: administering a preparation containing a bismuth compound in a topical dosage form.
- The said topical dosage form is selected from a group of options consisting of ointments, gels, creams, solutions, suspensions, emulsions, dressings, and aerosols. The bismuth compound is applied in an occlusive barrier to promote wound healing, or in a non-occlusive barrier to allow wound drainage, and to treating skin redness and erythema.
- Teicoplanin is used for its antimicrobial efficacy.
- Lidocaine gel is a local anesthetic agent.
- Verapamil, a calcium channel blocker which, selected from the group consisting of verapamil, nifedipine, diltiazem, amalodipine, felodipine, isradipine, nicardipine, nimodipine, nisoldipine, bepridil and mixtures thereof, is a non-invasive transdermal carrier agent, is used topically to improve wound healing by enhancing fibroblast proliferation, collagen bundle synthesis, and revascularization in skin injuries, preventing scar formation and treating existing scars as well.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CYPCT/CY2018/111997 | 2018-02-01 | ||
| CY2018111997 | 2018-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2019150173A1 true WO2019150173A1 (en) | 2019-08-08 |
Family
ID=61226623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2018/050695 WO2019150173A1 (en) | 2018-02-01 | 2018-02-05 | Tibo (topical innovative burn ointment) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019150173A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426085B1 (en) * | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US20150335704A1 (en) * | 2014-05-23 | 2015-11-26 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions comprising gels and methods for fabricating thereof |
-
2018
- 2018-02-05 WO PCT/IB2018/050695 patent/WO2019150173A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426085B1 (en) * | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US20150335704A1 (en) * | 2014-05-23 | 2015-11-26 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions comprising gels and methods for fabricating thereof |
Non-Patent Citations (5)
| Title |
|---|
| "Corygest", UNLISTED DRUGS, vol. 34, no. 3, March 1982 (1982-03-01), pages 38 |
| ARHANA CHATTOPADHYAY ET AL: "An Inexpensive Bismuth-Petrolatum Dressing for Treatment of Burns :", PLASTIC AND RECONSTRUCTIVE SURGERY GLOBAL OPEN, vol. 4, no. 6, 1 June 2016 (2016-06-01), pages e737, XP055510003, ISSN: 2169-7574, DOI: 10.1097/GOX.0000000000000741 * |
| DONNA MAXWELL: "Topical 2% lidocaine gel versus placebo in burn wound debridement pain - Donna Maxwell, J O'brien, G Sparkes, Dh Lalonde, 1996", 1 January 1996 (1996-01-01), XP055510032, Retrieved from the Internet <URL:http://journals.sagepub.com/doi/10.1177/229255039600400210> [retrieved on 20180926] * |
| J. A. STEER ET AL: "Teicoplanin versus flucloxacillin in the treatment of infection following burns", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY., vol. 39, no. 3, 1 March 1997 (1997-03-01), GB, pages 383 - 392, XP055510106, ISSN: 0305-7453, DOI: 10.1093/jac/39.3.383 * |
| RU WANG ET AL: "Role of verapamil in preventing and treating hypertrophic scars and keloids : Verapamil therapy for hypertrophic scars and keloids", INTERNATIONAL WOUND JOURNAL, vol. 13, no. 4, 12 May 2015 (2015-05-12), UK, pages 461 - 468, XP055510017, ISSN: 1742-4801, DOI: 10.1111/iwj.12455 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7731983B2 (en) | Method and composition for the treatment of scars | |
| CN104994843B (en) | Film-forming pharmaceutical composition for wound healing and method for preparing the same | |
| JP6495183B2 (en) | Compositions and methods for treating surface wounds | |
| US20140044667A1 (en) | Healing composition for topical application | |
| JP3550685B2 (en) | Wound healing agent | |
| KR101451816B1 (en) | Pharmaceutical Composition for Preventing or Treating Diabetic Wound | |
| WO2019150173A1 (en) | Tibo (topical innovative burn ointment) | |
| US6958159B2 (en) | Pharmaceutical gel composition | |
| RU2522214C1 (en) | Method for stimulating repair of wounds of various geneses with natural antioxidant dihydroquercetin | |
| RU2188016C1 (en) | Adhesive curative-prophylactic composition | |
| CA3092373A1 (en) | Topical wound care formulation | |
| KR102221499B1 (en) | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring | |
| GB2263234A (en) | Malotilate for accelerating wound healing | |
| RU2319484C1 (en) | Method for preventing purulent-septic complications in postsurgical period | |
| US20060009373A1 (en) | Method for treating diabetic wounds | |
| RU2210369C2 (en) | Method for preventing infectious complications at operation of mechanic dermabrasia at applying antiseptic preparation | |
| US10905729B1 (en) | Formulations and methods for wound treatment | |
| AU2001242100B2 (en) | Pharmaceutical gel composition | |
| JP2004262772A (en) | Glycyrrhizin-containing percutaneous pharmaceutical preparation | |
| KR20140104932A (en) | Pharmaceutical Composition for Preventing or Treating Diabetic Wound | |
| JPWO2021100027A5 (en) | ||
| Anastasiou | Maximilian Zenho & Co | |
| AU2001242100A1 (en) | Pharmaceutical gel composition | |
| KR20010007717A (en) | An ointment and gauze with anesthesia effect and sterilization | |
| HU202109B (en) | Process for producing pharmaceutical compositions containing nicotinic acid for treating leg ulcer, improving formation of a scar and inhiditing rough cicatrization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18705500 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22.12.2020) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18705500 Country of ref document: EP Kind code of ref document: A1 |